Integrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys

mAbs

Volumn 7, Issue 5, 2015, Pages 829-837

  Dudal, S ^a   Subramanian, K ^b   Flandre, T ^c   Law, W S ^d   Lowe, P J ^e   Skerjanec, A ^f   Genin, J C ^c   Duval, M ^c   Piequet, A ^c   Cordier, A ^c   Jarai, G ^g   Van Heeke, G ^h   Taplin, S ⁱ   Krantz, C ^c   Jones, S ^j   Warren, A P ^c   Brennan, F R ^k   Sims, J ^l   Lloyd, P ^m  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b Protein Sciences and Design   (United States)

^c Novartis Institute for BioMedical Research Basel   (Switzerland)

^d Merck Sharp and Dohme (MSD) Clintec   (Switzerland)

^e NOVARTIS PHARMA AG   (Switzerland)

^f Sandoz Pharma Ltd   (Switzerland)

^g BRISTOL MYERS SQUIBB   (United States)

^h ABLYNX NV   (Belgium)

ⁱ Forum IP Ltd   (United Kingdom)

^j ASTRAZENECA   (United Kingdom)

^k UCB PHARMA   (Belgium)

^l Integrated Biologix GmbH   (Switzerland)

^m KinDyn Consulting Ltd   (United Kingdom)

more..

Author keywords

Biotherapeutics; Chemokine; FIH predictions; MAb; Pharmacokinetics; PK PD model; Preclinical

Indexed keywords

ANTI CCL21 MONOCLONAL ANTIBODY; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; QBP359; SECONDARY LYMPHOID TISSUE CHEMOKINE; UNCLASSIFIED DRUG; CCL21 PROTEIN, HUMAN; IMMUNOGLOBULIN G;

ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG SAFETY; DRUG SYNTHESIS; FEMALE; IMMUNOASSAY; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; INFORMATION PROCESSING; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MACACA FASCICULARIS; MASS SPECTROMETRY; NONHUMAN; PHARMACODYNAMICS; PROTEIN EXPRESSION; SINGLE DRUG DOSE; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIBODY AFFINITY; HUMAN; IMMUNOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; CHEMOKINE CCL21; CHROMATOGRAPHY, LIQUID; HUMANS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; MACACA FASCICULARIS; MASS SPECTROMETRY;

EID: 84954313946     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1060384     Document Type: Article

References (33)

1. Namiki M, Kawashima S, Yamashita T, Ozaki M, Hirase T, Ishida T, Inoue N, Hirata K, Matsukawa A, Morishita R, et al. Local overexpression of monocyte chemoattractant protein-1 at vessel wall induces infiltration of macrophages and formation of atherosclerotic lesion: synergism with hypercholesterolemia. Arterioscler Thromb Vasc Biol 2002; 22:115-20; PMID:11788470; http://dx. doi. org/10. 1161/hq0102. 102278
2. Izikson L, Klein RS, Charo IF, Weiner HL, Luster AD. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J Exp Med 2000; 192:1075-80; PMID:11015448; http://dx. doi. org/10. 1084/jem. 192. 7. 1075
3. Shahrara S, Proudfoot AE, Park CC, Volin MV, Haines GK, Woods JM, Aikens CH, Handel TM, Pope RM. Inhibition of monocyte chemoattractant protein-1 ameliorates rat adjuvant-induced arthritis. J Immunol 2008; 180:3447-56; PMID:18292571; http://dx. doi. org/10. 4049/jimmunol. 180. 5. 3447
4. Moore BB, Paine R, 3rd, Christensen PJ, Moore TA, Sitterding S, Ngan R, Wilke CA, Kuziel WA, Toews GB. Protection from pulmonary fibrosis in the absence of CCR2 signaling. J Immunol 2001; 167:4368-77; PMID:11591761; http://dx. doi. org/10. 4049/jimmunol. 167. 8. 4368
5. Chung KF. Inflammatory mediators in chronic obstructive pulmonary disease. Curr Drug Targets Inflamm Allergy 2005; 4:619-25; PMID:17305518; http://dx. doi. org/10. 2174/156801005774912806
6. Youngs SJ, Ali SA, Taub DD, Rees RC. Chemokines induce migrational responses in human breast carcinoma cell lines. Int J Cancer 1997; 71:257-66; PMID:9139852; http://dx. doi. org/10. 1002/(SICI) 1097-0215(19970410)71:2%3c257::AIDIJC22% 3e3. 0. CO;2-D
7. Sun YX, Wang J, Shelburne CE, Lopatin DE, Chinnaiyan AM, Rubin MA, Pienta KJ, Taichman RS. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 2003; 89:462-73; PMID:12761880; http://dx. doi. org/ 10. 1002/jcb. 10522
8. Vanderkerken K, Vande Broek I, Eizirik DL, Van Valckenborgh E, Asosingh K, Van Riet I, Van Camp B. Monocyte chemoattractant protein-1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5T multiple myeloma cells. Clin Exp Metastasis 2002; 19:87-90; PMID:11918087; http:// dx. doi. org/10. 1023/A:1013891205989
9. Bai Z, Hayasaka H, Kobayashi M, Li W, Guo Z, Jang MH, Kondo A, Choi BI, Iwakura Y, Miyasaka M. CXC chemokine ligand 12 promotes CCR7-dependent naive T cell trafficking to lymph nodes and Peyer's patches. J Immunol 2009; 182:1287-95; PMID:19155474; http://dx. doi. org/10. 4049/ jimmunol. 182. 3. 1287
10. Forster R, Davalos-Misslitz AC, Rot A. CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol 2008; 8:362-71; PMID:18379575; http:// dx. doi. org/10. 1038/nri2297
11. Choi ES, Pierce EM, Jakubzick C, Carpenter KJ, Kunkel SL, Evanoff H, Martinez FJ, Flaherty KR, Moore BB, Toews GB, et al. Focal interstitial CC chemokine receptor 7 (CCR7) expression in idiopathic interstitial pneumonia. J Clin Pathol 2006; 59:28-39; PMID:16394278; http://dx. doi. org/10. 1136/jcp. 2005. 026872
12. Pierce EM, Carpenter K, Jakubzick C, Kunkel SL, Evanoff H, Flaherty KR, Martinez FJ, Toews GB, Hogaboam CM. Idiopathic pulmonary fibrosis fibroblasts migrate and proliferate to CC chemokine ligand 21. Eur Respir J 2007; 29:1082-93; PMID:17331965; http://dx. doi. org/10. 1183/09031936. 00122806
13. Pierce EM, Carpenter K, Jakubzick C, Kunkel SL, Flaherty KR, Martinez FJ, Hogaboam CM. Therapeutic targeting of CC ligand 21 or CC chemokine receptor 7 abrogates pulmonary fibrosis induced by the adoptive transfer of human pulmonary fibroblasts to immunodeficient mice. Am J Pathol 2007; 170:1152-64; PMID:17392156; http://dx. doi. org/10. 2353/ ajpath. 2007. 060649
14. Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, Furst DE, Harter JG, Levy G, Ludden T, Rodman JH, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. J Pharm Sci 1992; 81:605-10; PMID:1355792; http://dx. doi. org/10. 1002/jps. 2600810630
15. Vugmeyster Y, Harrold J, Xu X. Absorption, distribution, metabolism, and excretion (ADME) studies of biotherapeutics for autoimmune and inflammatory conditions. Aaps J 2012; 14:714-27; PMID:22798020; http://dx. doi. org/10. 1208/s12248-012-9385-y
16. Xu X, Vugmeyster Y. Challenges and opportunities in absorption, distribution, metabolism, and excretion studies of therapeutic biologics. Aaps J 2012; 14:781-91; PMID:22864668; http://dx. doi. org/10. 1208/ s12248-012-9388-8
17. Comerford I, Nibbs RJ, Litchfield W, Bunting M, Harata-Lee Y, Haylock-Jacobs S, Forrow S, Korner H, McColl SR. The atypical chemokine receptor CCXCKR scavenges homeostatic chemokines in circulation and tissues and suppresses Th17 responses. Blood 2010; 116:4130-40; PMID:20562329; http://dx. doi. org/10. 1182/blood-2010-01-264390
18. Nureki S, Miyazaki E, Ishi T, Ito T, Takenaka R, Ando M, Kumamoto T. Elevated concentrations of CCR7 ligands in patients with eosinophilic pneumonia. Allergy 2013; 68:1387-95; PMID:24111618; http:// dx. doi. org/10. 1111/all. 12243
19. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006; 354:610-21; PMID:16467548; http://dx. doi. org/10. 1056/NEJMra052723
20. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol 2001; 2:108-15; PMID:11175802; http:// dx. doi. org/10. 1038/84209
21. Harada K, Nakanuma Y. Innate immunity in the pathogenesis of cholangiopathy: a recent update. Inflamm Allergy Drug Targets 2012; 11:478-83; PMID:22920631; http://dx. doi. org/10. 2174/ 187152812803589976
22. Feng LY, Ou ZL, Wu FY, Shen ZZ, Shao ZM. Involvement of a novel chemokine decoy receptor CCX-CKR in breast cancer growth, metastasis and patient survival. Clin Cancer Res 2009; 15:2962-70; PMID:19383822; http://dx. doi. org/10. 1158/1078-0432. CCR-08-2495
23. Igawa T, Mimoto F, Hattori K. pH-dependent antigen-binding antibodies as a novel therapeutic modality. Biochim Biophys Acta 2014; 1844:1943-50; PMID:25125373; http://dx. doi. org/10. 1016/j. bbapap. 2014. 08. 003
24. Igawa T, Ishii S, Tachibana T, Maeda A, Higuchi Y, Shimaoka S, Moriyama C, Watanabe T, Takubo R, Doi Y, et al. Antibody recycling by engineered pHdependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol 2010; 28:1203-7; PMID:20953198; http://dx. doi. org/10. 1038/nbt. 1691
25. Chaparro-Riggers J, Liang H, DeVay RM, Bai L, Sutton JE, Chen W, Geng T, Lindquist K, Casas MG, Boustany LM, et al. Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. J Biol Chem 2012; 287:11090-7; PMID:22294692; http:// dx. doi. org/10. 1074/jbc. M111. 319764
26. Haringman JJ, Gerlag DM, Smeets TJ, Baeten D, van den Bosch F, Bresnihan B, Breedveld FC, Dinant HJ, Legay F, Gram H, et al. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54:2387-92; PMID:16869001; http://dx. doi. org/10. 1002/art. 21975
27. Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs 2011; 3:61-6; PMID:20962582; http:// dx. doi. org/10. 4161/mabs. 3. 1. 13799
28. Xiao JJ, Krzyzanski W, Wang YM, Li H, Rose MJ, Ma M, Wu Y, Hinkle B, Perez-Ruixo JJ. Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. Aaps J 2010; 12:646-57; PMID:20737261; http://dx. doi. org/ 10. 1208/s12248-010-9222-0
29. Fetterly GJ, Aras U, Meholick PD, Takimoto C, Seetharam S, McIntosh T, de Bono JS, Sandhu SK, Tolcher A, Davis HM, et al. Utilizing pharmacokinetics/ pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data. J Clin Pharmacol 2013; 53:1020-7; PMID:23878055; http://dx. doi. org/ 10. 1002/jcph. 140
30. Sandhu SK, Papadopoulos K, Fong PC, Patnaik A, Messiou C, Olmos D, Wang G, Tromp BJ, Puchalski TA, Balkwill F, et al. A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. Cancer Chemother Pharmacol 2013; 71:1041-50; PMID:23385782; http://dx. doi. org/10. 1007/s00280-013-2099-8
31. Chakraborty A, Tannenbaum S, Rordorf C, Lowe PJ, Floch D, Gram H, Roy S. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1beta monoclonal antibody. Clin Pharmacokinet 2012; 51:e1-18; PMID:22550964; http://dx. doi. org/10. 2165/11599820-000000000-00000
32. Lachmann HJ, Lowe P, Felix SD, Rordorf C, Leslie K, Madhoo S, Wittkowski H, Bek S, Hartmann N, Bosset S, et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009; 206:1029-36; PMID:19364880; http://dx. doi. org/10. 1084/jem. 20082481
33. Carlsen HS, Haraldsen G, Brandtzaeg P, Baekkevold ES. Disparate lymphoid chemokine expression in mice and men: no evidence of CCL21 synthesis by human high endothelial venules. Blood 2005; 106:444-6; PMID:15863780; http://dx. doi. org/10. 1182/blood-2004-11-4353